Advertisement
NBIX 外汇新闻
Neurocrine Biosciences Reaches Settlement On INGREZZA ANDA Litigation
Biopharmaceutical company Neurocrine Biosciences, Inc. (NBIX) announced Monday that is has resolved all patent litigation related to lawsuits resulting from Abbreviated New Drug Applications (ANDAs) brought by companies seeking approval to market a generic version of INGREZZA (valbenazine) prior to the expiration of applicable Neurocrine patents.
RTTNews
|
662天前
Neurocrine Biosciences Reports Positive Top-line Data From Phase 3 Study Of Crinecerfont
Neurocrine Biosciences, Inc. (NBIX) announced Tuesday positive top-line data from the Phase 3 CAHtalyst Adult Study evaluating the efficacy, safety, and tolerability of crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD).
RTTNews
|
724天前
